A monocentric retrospective cohort study assessing the MRI follow up of active perianal fistulizing Crohn's disease refractory to anti-tumor necrosis factor therapy receiving ustekinumab
Latest Information Update: 08 Dec 2021
Price :
$35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 08 Dec 2021 New trial record